Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Monoclonal antibodies (mAbs) Biosimilars Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Erythropoietin (EPO)
      • 1.3.3 Human Growth Hormone (HGH)
      • 1.3.4 Granulocyte- Colony Stimulating Factor (G-CSF)
      • 1.3.5 Monoclonal Antibody (mAb)
      • 1.3.6 Insulin
      • 1.3.7 Interferon (IFN)
      • 1.3.8 Others
    • 1.4 Market Segment by Application
      • 1.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Share by Application (2019-2025)
      • 1.4.2 Anti-Cancer
      • 1.4.3 Anti-Inflammatory/Autoimmune
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Global Monoclonal antibodies (mAbs) Biosimilars Market Size
      • 2.1.1 Global Monoclonal antibodies (mAbs) Biosimilars Revenue 2014-2025
      • 2.1.2 Global Monoclonal antibodies (mAbs) Biosimilars Sales 2014-2025
    • 2.2 Monoclonal antibodies (mAbs) Biosimilars Growth Rate by Regions
      • 2.2.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales by Regions 2014-2019
      • 2.2.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue by Regions 2014-2019
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Monoclonal antibodies (mAbs) Biosimilars Sales by Manufacturers
      • 3.1.1 Monoclonal antibodies (mAbs) Biosimilars Sales by Manufacturers 2014-2019
      • 3.1.2 Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Manufacturers 2014-2019
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Monoclonal antibodies (mAbs) Biosimilars Revenue by Manufacturers (2014-2019)
      • 3.2.2 Monoclonal antibodies (mAbs) Biosimilars Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Monoclonal antibodies (mAbs) Biosimilars Market Concentration Ratio (CR5 and HHI)
    • 3.3 Monoclonal antibodies (mAbs) Biosimilars Price by Manufacturers
    • 3.4 Key Manufacturers Monoclonal antibodies (mAbs) Biosimilars Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Monoclonal antibodies (mAbs) Biosimilars Market
    • 3.6 Key Manufacturers Monoclonal antibodies (mAbs) Biosimilars Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Sales and Revenue for Each Type
      • 4.1.1 Erythropoietin (EPO) Sales and Revenue (2014-2019)
      • 4.1.2 Human Growth Hormone (HGH) Sales and Revenue (2014-2019)
      • 4.1.3 Granulocyte- Colony Stimulating Factor (G-CSF) Sales and Revenue (2014-2019)
      • 4.1.4 Monoclonal Antibody (mAb) Sales and Revenue (2014-2019)
      • 4.1.5 Insulin Sales and Revenue (2014-2019)
      • 4.1.6 Interferon (IFN) Sales and Revenue (2014-2019)
      • 4.1.7 Others Sales and Revenue (2014-2019)
    • 4.2 Global Monoclonal antibodies (mAbs) Biosimilars Sales Market Share by Type
    • 4.3 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Market Share by Type
    • 4.4 Monoclonal antibodies (mAbs) Biosimilars Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Monoclonal antibodies (mAbs) Biosimilars Sales by Application

    6 United States

    • 6.1 United States Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Company
    • 6.2 United States Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
    • 6.3 United States Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application

    7 European Union

    • 7.1 European Union Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Company
    • 7.2 European Union Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
    • 7.3 European Union Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application

    8 China

    • 8.1 China Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Company
    • 8.2 China Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
    • 8.3 China Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application

    9 Rest of World

    • 9.1 Rest of World Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Company
    • 9.2 Rest of World Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Type
    • 9.3 Rest of World Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Application
    • 9.4 Rest of World Monoclonal antibodies (mAbs) Biosimilars Breakdown Data by Countries
      • 9.4.1 Rest of World Monoclonal antibodies (mAbs) Biosimilars Sales by Countries
      • 9.4.2 Rest of World Monoclonal antibodies (mAbs) Biosimilars Revenue by Countries
      • 9.4.3 Japan
      • 9.4.4 Korea
      • 9.4.5 India
      • 9.4.6 Southeast Asia

    10 Company Profiles

    • 10.1 Biocon
      • 10.1.1 Biocon Company Details
      • 10.1.2 Company Description and Business Overview
      • 10.1.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.1.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.1.5 Biocon Recent Development
    • 10.2 Celltrion
      • 10.2.1 Celltrion Company Details
      • 10.2.2 Company Description and Business Overview
      • 10.2.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.2.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.2.5 Celltrion Recent Development
    • 10.3 Dr. Reddy's Laboratories
      • 10.3.1 Dr. Reddy's Laboratories Company Details
      • 10.3.2 Company Description and Business Overview
      • 10.3.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.3.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.3.5 Dr. Reddy's Laboratories Recent Development
    • 10.4 Hospira
      • 10.4.1 Hospira Company Details
      • 10.4.2 Company Description and Business Overview
      • 10.4.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.4.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.4.5 Hospira Recent Development
    • 10.5 3SBio
      • 10.5.1 3SBio Company Details
      • 10.5.2 Company Description and Business Overview
      • 10.5.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.5.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.5.5 3SBio Recent Development
    • 10.6 Accord Healthcare
      • 10.6.1 Accord Healthcare Company Details
      • 10.6.2 Company Description and Business Overview
      • 10.6.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.6.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.6.5 Accord Healthcare Recent Development
    • 10.7 AET Biotech
      • 10.7.1 AET Biotech Company Details
      • 10.7.2 Company Description and Business Overview
      • 10.7.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.7.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.7.5 AET Biotech Recent Development
    • 10.8 Allergan
      • 10.8.1 Allergan Company Details
      • 10.8.2 Company Description and Business Overview
      • 10.8.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.8.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.8.5 Allergan Recent Development
    • 10.9 Amega Biotech
      • 10.9.1 Amega Biotech Company Details
      • 10.9.2 Company Description and Business Overview
      • 10.9.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.9.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.9.5 Amega Biotech Recent Development
    • 10.10 Others
      • 10.10.1 Others Company Details
      • 10.10.2 Company Description and Business Overview
      • 10.10.3 Sales, Revenue and Market Share of Monoclonal antibodies (mAbs) Biosimilars
      • 10.10.4 Monoclonal antibodies (mAbs) Biosimilars Product Introduction
      • 10.10.5 Others Recent Development

    11 Value Chain and Sales Channels Analysis

    • 11.1 Value Chain Analysis
    • 11.2 Sales Channels Analysis
      • 11.2.1 Monoclonal antibodies (mAbs) Biosimilars Sales Channels
      • 11.2.2 Monoclonal antibodies (mAbs) Biosimilars Distributors
    • 11.3 Monoclonal antibodies (mAbs) Biosimilars Customers

    12 Market Forecast

    • 12.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales and Revenue Forecast 2019-2025
    • 12.2 Global Monoclonal antibodies (mAbs) Biosimilars Sales Forecast by Type
    • 12.3 Global Monoclonal antibodies (mAbs) Biosimilars Sales Forecast by Application
    • 12.4 Monoclonal antibodies (mAbs) Biosimilars Forecast by Regions
      • 12.4.1 Global Monoclonal antibodies (mAbs) Biosimilars Sales Forecast by Regions 2019-2025
      • 12.4.2 Global Monoclonal antibodies (mAbs) Biosimilars Revenue Forecast by Regions 2019-2025
    • 12.5 United States Market Forecast
    • 12.6 European Union Market Forecast
    • 12.7 China Market Forecast
    • 12.8 Rest of World
      • 12.8.1 Japan
      • 12.8.2 Korea
      • 12.8.3 India

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Research Methodology
        • 14.1.1 Methodology/Research Approach
          • 14.1.1.1 Research Programs/Design
          • 14.1.1.2 Market Size Estimation
          • 14.1.1.3 Market Breakdown and Data Triangulation
        • 14.1.2 Data Source
          • 14.1.2.1 Secondary Sources
          • 14.1.2.2 Primary Sources
      • 14.2 Author Details

      A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
      According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
      In 2019, the market size of Monoclonal antibodies (mAbs) Biosimilars is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Monoclonal antibodies (mAbs) Biosimilars.

      This report studies the global market size of Monoclonal antibodies (mAbs) Biosimilars, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Monoclonal antibodies (mAbs) Biosimilars sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      Biocon
      Celltrion
      Dr. Reddy's Laboratories
      Hospira
      3SBio
      Accord Healthcare
      AET Biotech
      Allergan
      Amega Biotech
      Others

      Market Segment by Product Type
      Erythropoietin (EPO)
      Human Growth Hormone (HGH)
      Granulocyte- Colony Stimulating Factor (G-CSF)
      Monoclonal Antibody (mAb)
      Insulin
      Interferon (IFN)
      Others

      Market Segment by Application
      Anti-Cancer
      Anti-Inflammatory/Autoimmune

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Monoclonal antibodies (mAbs) Biosimilars status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Monoclonal antibodies (mAbs) Biosimilars manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Monoclonal antibodies (mAbs) Biosimilars are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now